QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
Log in
NASDAQ:SNSS

Sunesis Pharmaceuticals Stock Forecast, Price & News

$1.17
-0.12 (-9.30 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.16
Now: $1.17▼
$1.29
50-Day Range
$1.17
MA: $1.36▼
$1.52
52-Week Range
$1.16
Now: $1.17▼
$11.30
Volume992,940 shs
Average Volume720,833 shs
Market Capitalization$21.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Sunesis Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
Previous Symbol
CUSIP86732860
CIK1061027
Webwww.sunesis.com
Phone650-266-3500
Employees24

Debt

Debt-to-Equity RatioN/A
Current Ratio2.65
Quick Ratio2.65

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.07 million
Price / Sales10.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.42 per share
Price / Book0.82

Profitability

EPS (Most Recent Fiscal Year)($2.70)
Net Income$-23,330,000.00
Net MarginsN/A
Return on Equity-183.63%
Return on Assets-68.89%

Miscellaneous

Outstanding Shares18,093,000
Market Cap$21.17 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$1.17
-0.12 (-9.30 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

How has Sunesis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Sunesis Pharmaceuticals' stock was trading at $6.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SNSS shares have decreased by 81.4% and is now trading at $1.17.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Sunesis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Sunesis Pharmaceuticals.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Sunesis Pharmaceuticals.

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its earnings results on Tuesday, August, 11th. The biopharmaceutical company reported ($0.60) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.60).
View Sunesis Pharmaceuticals' earnings history.

When did Sunesis Pharmaceuticals' stock split? How did Sunesis Pharmaceuticals' stock split work?

Sunesis Pharmaceuticals shares reverse split on Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of Sunesis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SNSS?

4 analysts have issued twelve-month price targets for Sunesis Pharmaceuticals' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 541.0% from the stock's current price.
View analysts' price targets for Sunesis Pharmaceuticals.

Are investors shorting Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 609,800 shares, a decline of 21.2% from the September 30th total of 773,700 shares. Based on an average daily trading volume, of 1,570,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.4% of the company's stock are short sold.
View Sunesis Pharmaceuticals' Short Interest.

Who are some of Sunesis Pharmaceuticals' key competitors?

Some companies that are related to Sunesis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SELLAS Life Sciences Group (SLS), Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the following people:
  • Mr. Dayton Misfeldt, Principal Financial Officer, Sec., Interim CEO & Director (Age 46, Pay $40k)
  • Dr. Judith A. Fox, Chief Scientific Officer and Exec. VP of R&D (Age 63, Pay $477.01k)
  • Mr. William P. Quinn, Consultant (Age 49, Pay $476.72k)
  • Ms. Tina Gullotta, VP of Fin. & Principal Accounting Officer (Age 46)
  • Mr. Stephen Nava, VP of Quality Assurance, Compliance & Regulatory Affairs

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $1.17.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $21.17 million and generates $2.07 million in revenue each year. The biopharmaceutical company earns $-23,330,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. Sunesis Pharmaceuticals employs 24 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.